$TCRT

Alaunos Therapeutics (TCRT) regained compliance with Nasdaq's $2.5M stockholders' equity requirement, avoiding delisting. The company completed a private placement financing on October 14, 2026, which Nasdaq confirmed restored compliance. The delisting hearing scheduled for November 10, 2026, was canceled. Alaunos still faces risks related to equity, stockholder approvals, and future compliance.

Alaunos Therapeutics, Inc. (TCRT) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on April 9, 2026, Alaunos Therapeutics, Inc. (the “Company”) received a written notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in comp

Fairmount Funds Management LLC disclosed a 19.99% stake in Alaunos Therapeutics, Inc. (TCRT) through a Schedule 13D filing. The investment includes preferred-share rights and potential board changes, with Fairmount designees set to fill three of five board seats upon shareholder approval. The stake is capped at 19.99% and will reduce to 9.99% if ownership falls below 9%. Fairmount backed Alaunos's merger with Velaris and a $350 million financing.

Alaunos Therapeutics (TCRT) stock surged 146.67% to $2.59 on news of acquiring Velaris Therapeutics and a $350M private placement. The acquisition expands Alaunos' pipeline with therapies for pulmonary arterial hypertension and related conditions. The company expects financial runway into 2029, with proof-of-concept data for VLR199 anticipated in 2028.

Alaunos Therapeutics, Inc. (TCRT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Transaction & Corporate Overview October 2026 Confidential Disclaimers and forward-looking statements Disclaimer This presentation has been prepared by Velaris Therapeutics, Inc. (“Velaris” or the “Company”). The information contained herein is provided as of the date hereof, is

Paragon Labs added former Apogee executives to its leadership team. Alaunos Therapeutics (TCRT) acquired Velaris Therapeutics, a biotech company focused on pulmonary hypertension therapies. Velaris is the ninth company launched around Paragon-discovered assets. Alaunos completed the acquisition, expanding its portfolio of ActRII-Fc ligand traps and biologics.

Alaunos Therapeutics (TCRT) received a delisting notice from Nasdaq for failing to meet the $2.5M stockholders' equity requirement. The company plans to request a hearing to contest the delisting.

Alaunos Therapeutics, Inc. (TCRT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules FORT LAUDERDALE, Fla., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today announced that it has entered into definitive agreements wi

Alaunos Therapeutics (TCRT) raised $1.12M via a registered direct offering of 380,469 shares and pre-funded warrants at $1.46 per share. Proceeds will fund working capital and corporate purposes. The offering is expected to close on or around September 21, 2026. TCRT stock closed at $1.60 on Thursday, up 25.00%, and was at $1.44 in pre-market trading, down 8.13%.

Alaunos Therapeutics (TCRT) fell 16.81% to $1.3303 after announcing a $1.12M stock offering. The deal includes 380,469 shares and warrants at $1.46 per share, set to close by September 21, 2026. Proceeds will fund working capital. The stock's 52-week range is $1.27 to $4.59.